Ignite Creation Date:
2024-05-06 @ 11:09 AM
Last Modification Date:
2024-10-26 @ 12:40 PM
Study NCT ID:
NCT03440736
Status:
COMPLETED
Last Update Posted:
2023-05-22
First Post:
2018-01-31
Brief Title:
Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Metabolic Syndrome |
| Psoriasis |
Keywords:
| Name | View |
|---|---|
| itching | View |
| Psoriasis | View |
| Metabolic syndrome | View |
| Diabetes | View |
| Obesity | View |
| Life-style | View |
| Life-style intervention | View |
| Secukinumab | View |
| CAIN457A | View |
| CAIN457ADE08 | View |
| AIN457A | View |
| Skin condition | View |
| skin disease | View |
| itching condition | View |
| psoriasis vulgaris | View |
| relapsing psoriasis | View |
| remitting psoriasis | View |
| immune-mediated systemic disease | View |
| skin lesions | View |
| red skin lesions | View |
| scaly patches | View |
| papules | View |
| plaques | View |